Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00069927 · ClinicalTrials.gov registry record · Phase 2

Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression

A Phase 2 study, sponsored by University of South Florida.

Terminated
Registry status
Phase 2
Development phase
12
Enrollment target

NCT00069927 is a Phase 2 study that was terminated before completion, run by University of South Florida. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00069927, a Phase 2 study, was terminated before completion, sponsored by University of South Florida.

TERMINATED
Registry status
Phase 2
Development phase
12 participants
Enrollment target

Study Summary

RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression. PURPOSE: This randomized phase II trial is studying dextroamphetamine-amphetamine to see how well it works compared to methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer. This trial will also study how often depression is seen and if these medications might help.

Interventions

  • DRUG Adderall-XR®
  • DRUG Concerta®

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2003-08
Est. Completion 2006-09
Phase Phase 2

Sponsor

University of South Florida

252 total trials

What the Registry Record Tells You About NCT00069927

The ClinicalTrials.gov registry entry for NCT00069927 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Adderall-XR® is the first listed.

NCT00069927 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00069927 about?

NCT00069927 is a clinical study titled "Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression". RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression. PURPOSE: This randomized phase II trial is studying dextroamp...

What is the current status of trial NCT00069927?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2003-08. Estimated completion is 2006-09.

What interventions are being tested in trial NCT00069927?

The interventions under investigation include: Adderall-XR® (DRUG), Concerta® (DRUG).

Who is sponsoring clinical trial NCT00069927?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.